This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 12
  • /
  • EUSA Pharma announces first patient enrolled in ph...
News

EUSA Pharma announces first patient enrolled in phase III trial investigating siltuximab in hospitalised patients with COVID-19- or acute respiratory distress syndrome (ARDS).

Read time: 1 mins
Published:20th Dec 2020
EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19. The phase III SILVAR study will evaluate the efficacy and safety of standard of care (SOC), both with and without intravenous siltuximab treatment in patients hospitalised with COVID-19. The selected patients chosen for the SILVAR study will have also been previously treated with corticosteroids or have also had another respiratory infection. In addition, the SILVAR study will only enroll hospitalised patients suffering from serious viral acute respiratory distress syndrome (ARDS) in a hyperinflammatory state.
Condition: Coronavirus/ARDS
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.